Palisade Bio Inc reports results for the quarter ended in December - Earnings Summary

Palisade Bio

26/03/2024 21:41

* Palisade Bio Inc  PALI.OQ  reported a quarterly adjusted
loss
of 43 cents​​ per share for the quarter ended in December, lower
than the same quarter last year, when the company reported EPS
of $6.47.  The mean expectation of two analysts for the quarter
was for a loss of 34 cents per share. Wall Street expected
results to range from -36 cents to -33 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Palisade Bio Inc's reported EPS for the quarter was a loss
of 43
cents​.
    * The company reported a quarterly loss of $2.97 million.
    * Palisade Bio Inc shares had fallen by 38.5% this quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "buy."

Wall Street's median 12-month price target for Palisade Bio Inc
is $2.25 
This summary was machine generated from LSEG data March 26 at
09:41 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.34          -0.43          Missed
 Sep. 30 2023      -0.39          -0.44          Missed
 Jun. 30 2023      -0.45          -0.53          Missed
 Mar. 31 2023      -0.72          -0.54          Beat